Drug Trial Radar · NCT07833098
A Phase II Study of VB19055 in Uncontrolled or Resistant Hypertension
Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Dec 2027
Study completion Feb 2028
Sponsor
- Lead sponsor
- Zhejiang Yangli Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase II trial of VB19055 for 12 weeks in 240 adults with uncontrolled hypertension (including resistant hypertension).
Conditions
- Hypertension
- Resistant Hypertension
- Uncontrolled Hypertension
Interventions
VB19055 Dose A QDDrug
VB19055 Dose A orally once daily (QD) for 12 weeks
VB19055 Dose B QDDrug
VB19055 DoseB orally once daily (QD) for 12 weeks
VB19055 Dose C QDDrug
VB19055 Dose C orally once daily (QD) for 12 weeks
VB19055 placebo QDDrug
VB19055 placebo orally once daily (QD) for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in seated clinic systolic blood pressure at Week 12.Time frame: at the end of the 12-week treatment period
Locations
24 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology
Baotou, China
Peking University People's Hospital
Beijing, China
The Third Hospital of Changsha
Changsha, China
The Third Xiangya Hospital of Central South University
Changsha, China
Chengdu Second People's Hospital
Chengdu, China
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, China
Daqing People's Hospital
Daqing, China
The First Hospital of Hebei Medical University
Hebei, China
The First Affiliated Hospital of University of South China
Hengyang, China
Affiliated Hospital of Jining Medical University
Jining, China
The Third People's Hospital of Luoyang
Luoyang, China
Zhongda Hospital, Southeast University
Nanjing, China
Panjin Liaohe Oilfield Gem Flower Hospital
Panjin, China
Qilu Hospital of Shandong University
Shandong, China
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China
Shanxi Cardiovascular Hospital
Shaxi, China
Liaoning Provincial People's Hospital
Shenyang, China
Shengjing Hospital of China Medical University
Shenyang, China
Suzhou Municipal Hospital of Anhui Province
Suzhou, China
China Resources WISCO General Hospital
Wuhan, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
The First People's Hospital of Xinxiang
Xinxiang, China
The Seventh People's Hospital of Zhengzhou City
Zhengzhou, China
Zhengzhou Central Hospital
Zhengzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.